| pubmed-article:21045734 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21045734 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21045734 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21045734 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:21045734 | lifeskim:mentions | umls-concept:C0034787 | lld:lifeskim |
| pubmed-article:21045734 | lifeskim:mentions | umls-concept:C0205081 | lld:lifeskim |
| pubmed-article:21045734 | lifeskim:mentions | umls-concept:C0205318 | lld:lifeskim |
| pubmed-article:21045734 | lifeskim:mentions | umls-concept:C1962523 | lld:lifeskim |
| pubmed-article:21045734 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21045734 | pubmed:dateCreated | 2010-12-16 | lld:pubmed |
| pubmed-article:21045734 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:abstractText | Many angiotensin receptor blocker (ARB) monotherapy patients need at least two agents to control blood pressure (BP). We investigated whether initiating intensive treatment with combination amlodipine/valsartan was superior to moderate treatment with amlodipine/valsartan in patients previously uncontrolled on ARB monotherapy. | lld:pubmed |
| pubmed-article:21045734 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21045734 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21045734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21045734 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21045734 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:21045734 | pubmed:issn | 1473-5598 | lld:pubmed |
| pubmed-article:21045734 | pubmed:author | pubmed-author:OparilSuzanne... | lld:pubmed |
| pubmed-article:21045734 | pubmed:author | pubmed-author:PittBertramB | lld:pubmed |
| pubmed-article:21045734 | pubmed:author | pubmed-author:SowersJames... | lld:pubmed |
| pubmed-article:21045734 | pubmed:author | pubmed-author:OfiliElizabet... | lld:pubmed |
| pubmed-article:21045734 | pubmed:author | pubmed-author:GilesThomasT | lld:pubmed |
| pubmed-article:21045734 | pubmed:author | pubmed-author:SeifuYoditY | lld:pubmed |
| pubmed-article:21045734 | pubmed:author | pubmed-author:HilkertRobert... | lld:pubmed |
| pubmed-article:21045734 | pubmed:author | pubmed-author:SamuelRitaR | lld:pubmed |
| pubmed-article:21045734 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21045734 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:21045734 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21045734 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21045734 | pubmed:pagination | 161-70 | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:meshHeading | pubmed-meshheading:21045734... | lld:pubmed |
| pubmed-article:21045734 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21045734 | pubmed:articleTitle | Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. | lld:pubmed |
| pubmed-article:21045734 | pubmed:affiliation | Department of Medicine –Cardiovascular, University of Alabama at Birmingham, Birmingham, Alabama 35294-1150, USA. suzanne.oparil@ccc.uab.edu | lld:pubmed |
| pubmed-article:21045734 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21045734 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21045734 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21045734 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21045734 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
